Servier Canada, CQDM partner in diabetes research project

The International pharmaceutical company, Servier Canada is working with the Quebec-based industrial cluster CQDM to fund a research project aimed at preventing diabetes-related kidney diseases.

This public-private partnership globally valued at $1.5 million will allow the team of Dr. Pavel Hamet at the CHUM (CRCHUM) Research Centre to identify biomarkers and genetic profiles associated with chronic kidney disease caused by diabetes. This programme will support the development of several preventive tests. The first one will be marketed within two years by OPTI-THERA, a Quebec biotech company that specializes in diabetes.

“The chronic kidney disease is affecting one in two diabetic patients, and its end stage requires heavy and costly interventions, like dialysis or renal transplant. The purpose of this project is to develop new predictive tools, able to identify diabetic patients most susceptible to develop renal insufficiency in order to treat them earlier, in primary prevention ” , said Dr. Pavel Hamet, who holds a Canada Research Chair in Predictive Genomics at CRCHUM.

This project is funded through CQDM’s SynergiQc program thanks to a contribution of $333 475 from the Ministry of Economy, Science and Innovation. The purpose of this program is to fund research programs from Industry which is implemented in the academic settings and thereby allow Quebec companies to break new ground while benefiting from the expertise found in Quebec universities.

“CQDM is proud to welcome Servier, a world leader in the pharmaceutical industry, as a new member of its research consortium. Through its commitment to this project, Servier will have a major impact on the health status of patients suffering from diabetes, by delaying the onset of chronic kidney disease, one of the most devastating vascular complication of diabetes”, said Ms. Diane Gosselin, president and CEO of CQDM.

The development of tools for treating such diseases as diabetes, combines biomarkers and genetic testing is necessary to reach a significant and reliable predictive value for vascular complications. These tools are part of a precision medicine approach which aims at treating earlier the most vulnerable patients, since the current available treatment options to prevent renal complications are more efficient in primary prevention, i.e. before symptoms appear.

“The partnerships we are implementing here, are key to accelerate and complement our international research programs. We are proud to partner with CQDM and OPTI-THERA to actively contribute to improving the health status of diabetic patients”, said Servier Canada chief executive officer Frédéric Fasano.

 

 

 

Be the first to comment

Leave a Reply

Your email address will not be published.


*